An adjuvanted, #trivalent #influenzavaccine developed by #CSLSeqirus and recently approved in the #UK, #Aujemflu, will be deployed ahead of the 2027/28 #fluseason under an agreement with the government.
pharmaphorum.com/news/uk-firs...
pharmaphorum.com/news/uk-firs...
UK first country to launch CSL's trivalent flu shot Aujemflu
CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.
pharmaphorum.com
September 22, 2026 at 9:47 AM
An adjuvanted, #trivalent #influenzavaccine developed by #CSLSeqirus and recently approved in the #UK, #Aujemflu, will be deployed ahead of the 2027/28 #fluseason under an agreement with the government.
pharmaphorum.com/news/uk-firs...
pharmaphorum.com/news/uk-firs...
Adjuvanted trivalent flu vaccine approved for over 50s 💉
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the MHRA for use in adults aged 50 years and older.
Read it here 👇️
🔗 buff.ly/l5VhxEa
#Aujemflu #influenza #vaccine #MHRA #Over50s #OlderAdults
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the MHRA for use in adults aged 50 years and older.
Read it here 👇️
🔗 buff.ly/l5VhxEa
#Aujemflu #influenza #vaccine #MHRA #Over50s #OlderAdults
Adjuvanted trivalent flu vaccine approved for over 50s
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults aged 50 years and older. The vaccine,…
buff.ly
June 24, 2026 at 8:04 PM
Adjuvanted trivalent flu vaccine approved for over 50s 💉
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the MHRA for use in adults aged 50 years and older.
Read it here 👇️
🔗 buff.ly/l5VhxEa
#Aujemflu #influenza #vaccine #MHRA #Over50s #OlderAdults
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the MHRA for use in adults aged 50 years and older.
Read it here 👇️
🔗 buff.ly/l5VhxEa
#Aujemflu #influenza #vaccine #MHRA #Over50s #OlderAdults
The committee recommended granting a marketing authorisation for Aujemflu (influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated), a vaccine to protect people aged 50 years and older against influenza.
June 26, 2026 at 11:11 AM
The committee recommended granting a marketing authorisation for Aujemflu (influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated), a vaccine to protect people aged 50 years and older against influenza.
Groundbreaking Influenza Vaccine Promises Enhanced Protection for Seniors#United_Kingdom#CSL_Seqirus#Maidenhead#aQIVc#AUJEMFLU
Groundbreaking Influenza Vaccine Promises Enhanced Protection for Seniors
A recent study reveals an innovative influenza vaccine combining three advanced methods for better protection in older adults. Learn more about this milestone in flu prevention.
third-news.com
September 10, 2026 at 10:48 PM
Groundbreaking Influenza Vaccine Promises Enhanced Protection for Seniors#United_Kingdom#CSL_Seqirus#Maidenhead#aQIVc#AUJEMFLU
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults aged 50 years and older.
#Influenza #MHRA #Vaccine
#Influenza #MHRA #Vaccine
Adjuvanted trivalent flu vaccine approved for over 50s
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults aged 50 years and older. The vaccine,…
buff.ly
July 1, 2026 at 3:06 PM
Aujemflu, an adjuvanted trivalent influenza vaccine, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults aged 50 years and older.
#Influenza #MHRA #Vaccine
#Influenza #MHRA #Vaccine